drugset

Drugs / PRADUSINSTOBART

Follow last change Jul 2024 re-read 2 minutes ago

PRADUSINSTOBART

also known as LVGN3616

Monoclonal antibody

Developed for: esophageal cancer · gastric cancer · head and neck carcinoma · hepatocellular carcinoma · ovarian carcinoma · soft tissue sarcoma · uveal melanoma · virus associated tumor
+1 more
· head and neck squamous cell carcinoma
Investigated by: Lyvgen Biopharma Holdings Limited · M.D. Anderson Cancer Center

Trials 1 · a red edge is where a trial was stopped

today NCT05075993 · Ph 1

202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT05075993	Nov 2021 → Feb 2027 expected	esophageal cancer, gastric cancer, head and neck carcinoma, hepatocellular carcinoma +4	M.D. Anderson Cancer Center	Active not recruiting	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT06159621 Comparator	Jul 2024 → Mar 2028 expected	head and neck squamous cell carcinoma	University of Pennsylvania	Active not recruiting	No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	PRADUSINSTOBART	ChEMBL registry synonym — accepted as the source's own label CHEMBL5314701 ↗
Known as	LVGN3616	“This will be a prospective, open-label, window of opportunity study of LVGN7409 and LVGN3616 (or nivolumab) in resectable HPV-negative HNSCC with co-primary endpoints of safety...” NCT06159621 ↗ 2 NCT06159621 ↗ NCT05075993 ↗
Action	Inhibit	“PD-1 inhibition (LVGN3616 or nivolumab)” NCT06159621 ↗
Modality	Monoclonal antibody	— CHEMBL5314701 ↗